MARIMED INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
MRMDStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash, cash equivalents and restricted cash | $8,884 | $7,282 |
| Accounts receivable, net | 9,114 | 8,742 |
| Inventory | 36,601 | 33,488 |
| Deferred rents receivable | — | 556 |
| Notes receivable, current portion | 866 | 52 |
| Other current assets | 3,825 | 3,389 |
| Total current assets | 59,290 | 53,509 |
| Property and equipment, net | 89,385 | 94,167 |
| Intangible assets, net | 17,210 | 18,639 |
| Goodwill | 24,002 | 15,812 |
| Notes receivable, net of current portion | — | 840 |
| Operating lease right-of-use assets | 7,723 | 8,730 |
| Finance lease right-of-use assets | 4,024 | 4,073 |
| Other assets | 931 | 11,219 |
| Total assets | $202,565 | $206,989 |
| Liabilities, mezzanine equity and stockholders’ equity | ||
| Current liabilities: | ||
| Mortgages and notes payable, current portion | $2,553 | $5,126 |
| Accounts payable | 14,586 | 13,189 |
| Accrued expenses and other | 9,509 | 4,435 |
| Deferred revenue | 1,394 | 1,329 |
| Income taxes payable | 26,981 | 21,922 |
| Operating lease liabilities, current portion | 1,952 | 1,988 |
| Finance lease liabilities, current portion | 2,092 | 2,018 |
| Total current liabilities | 59,067 | 50,007 |
| Mortgages and notes payable, net of current portion | 70,192 | 69,860 |
| Operating lease liabilities, net of current portion | 6,616 | 7,549 |
| Finance lease liabilities, net of current portion | 1,956 | 1,926 |
| Other liabilities | — | 100 |
| Total liabilities | 137,831 | 129,442 |
| Commitments and contingencies | ||
| Mezzanine equity: | ||
| Series B convertible preferred stock, $0.001 par value; 4,908,333 shares authorized, issued and outstanding at December 31, 2025 and 2024 | 14,725 | 14,725 |
| Series C convertible preferred stock, $0.001 par value; 12,432,432 shares authorized; zero and 1,155,274 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | 4,275 |
| Total mezzanine equity | 14,725 | 19,000 |
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Stockholders’ equity: | ||
| Undesignated preferred stock, $0.001 par value; 32,659,235 shares authorized; zero shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; 700,000,000 shares authorized; 396,911,368 and 381,476,581 shares issued and outstanding at December 31, 2025 and 2024, respectively | 397 | 381 |
| Additional paid-in capital | 179,405 | 173,366 |
| Accumulated deficit | (127,932) | (113,448) |
| Noncontrolling interests | (1,861) | (1,752) |
| Total stockholders’ equity | 50,009 | 58,547 |
| Total liabilities, mezzanine equity, and stockholders’ equity | $202,565 | $206,989 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.